Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:37:38.842Z.
Calculation as of: 2026-10-06T16:37:38.842Z.
Quote observation: 2026-10-06T16:34:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$24.44M
EV/FCF Ratio
N/A
TTM Avg
248.89x
3Y Avg
248.89x
5Y Avg
248.89x
Market Cap
$27.70M
EV/FCF Ratio
N/A
TTM Avg
130.14x
3Y Avg
130.14x
5Y Avg
55.86x
Market Cap
$22.31M
EV/FCF Ratio
4.34x
TTM Avg
11.24x
3Y Avg
10.04x
5Y Avg
10.04x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $25.57M | N/A | N/A | N/A | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.74M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.44M | N/A | 248.89x | 248.89x | 248.89x |
| Kyntra Bio, Inc. (KYNB)vs › | $24.38M | N/A | 104.27x | 104.96x | 131.27x |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.70M | N/A | 130.14x | 130.14x | 55.86x |
| InspireMD, Inc. (NSPR)vs › | $28.10M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $22.97M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.50M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.31M | 4.34x | 11.24x | 10.04x | 10.04x |
| LeonaBio, Inc. (LONA)vs › | $22.24M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
